Achievements

Trial status April 2020

In Africa

The aim of the EBL2002 study in Africa is to test the vaccine for safety and immunogenicity in a total of 1,056 study participants including healthy adults and population groups including the elderly, HIV-infected adults, adolescents and children. In total, 1,885 participants have been screened and 1,075 have been randomized across cohort 1 (669 healthy adults), cohort 2A (142 HIV-infected individuals), cohort 2B (132 healthy adolescents aged 12 to 17 years) and cohort 3 (132 children aged 4 to 11 years) of which 1,017 have received the Dose 2 vaccination. 

A booster dose (Ad26.ZEBOV) was given to 90 study participants to confirm the establishment of memory and development of an anamnestic response. 

All study cohorts are now completed. Sample analyses are still ongoing on cohort 2B (132 healthy adolescents aged 12 to 17 years) and cohort 3 (132 children aged 4 to 11 years).

In Europe

The EBL2001 trial in Europe (UK, France) has been completed. 423 study participants have been randomized (143 were randomized in reporting year 1 and 280 in reporting year 2), of which 290 have received the second dose vaccination. The site close-out visits have been performed. Volunteers are now being followed for five years in a long-term safety follow-up study, EBL4001.

Sample core analysis has been completed in the US for the main immune response. The focus is now on the additional immunogenicity testing conducted in France and in the UK.

From a scientific perspective

Thanks to the finalisation of Cohort 1, the first results in EBOVAC2 on the immune response to the vaccine were obtained by the Oxford Vaccine Group (UOXF) in a subcohort of 30 participants in the UK.  During the last 12 months, UOXF has been characterising the B cell response to Ad26.ZEBOV/MVA.BN.Filo and has shown strong plasma cell responses and also identified their phenotypes. The group has also begun preliminary analysis of the antibody VH-gene response post Ad prime and MVA boost and initial isolation of monoclonal antibodies has been achieved by the Townsend group.

NEWS

  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA

Cookies settings

×

Functional Cookies

This site uses cookies to ensure its proper functioning and cannot be deactivated from our systems. We do not use them for advertising purposes. If these cookies are blocked, certain parts of the site will not be able to function.

Measure of audience

This site uses audience measurement and analysis cookies, such as Google Analytics, in order to evaluate and improve our website.

Interactive Content

This site uses third-party components, such as ReCAPTCHA, Google Maps, which may deposit cookies on your machine. If you decide to block a component, the content will not be displayed

Other cookies

Our wepage uses cookies to manage user sessions